Bisphosphonate drug holidays
- PMID: 31616961
- PMCID: PMC8055376
- DOI: 10.1007/s00198-019-05107-2
Bisphosphonate drug holidays
Conflict of interest statement
Conflict of Interest:
Smita Nayak declares no conflict of interest.
Comment on
-
A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.Osteoporos Int. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. Epub 2019 Jan 8. Osteoporos Int. 2019. PMID: 30623214 Free PMC article.
-
Drug holidays in osteoporosis treatment: mind the gaps!Osteoporos Int. 2019 Dec;30(12):2523-2524. doi: 10.1007/s00198-019-05027-1. Epub 2019 Oct 15. Osteoporos Int. 2019. PMID: 31616960 No abstract available.
References
-
- Anagnostis P, Paschou SA, Mintziori G, et al. (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23–30 - PubMed
-
- Watts NB, Chines A, Olszynski WP, et al. (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
